Evista: Advanced Osteoporosis Protection with Raloxifene
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.67 | $50.22 (0%) | 🛒 Add to cart |
| 60 | $1.31 | $100.44 $78.35 (22%) | 🛒 Add to cart |
| 90 | $1.18 | $150.67 $106.47 (29%) | 🛒 Add to cart |
| 120 | $1.13 | $200.89 $135.60 (32%) | 🛒 Add to cart |
| 180 | $1.07 | $301.33 $191.85 (36%) | 🛒 Add to cart |
| 270 | $1.03 | $452.00 $277.23 (39%) | 🛒 Add to cart |
| 360 | $1.01
Best per pill | $602.66 $362.60 (40%) | 🛒 Add to cart |
Synonyms | |||
Evista (raloxifene hydrochloride) is a selective estrogen receptor modulator (SERM) specifically engineered for postmenopausal women seeking robust bone density preservation and fracture risk reduction. By mimicking estrogen’s beneficial effects on bone without stimulating uterine or breast tissue, it offers a targeted therapeutic approach. Clinically proven to increase bone mineral density and lower vertebral fracture incidence, Evista represents a cornerstone in long-term osteoporosis management, combining efficacy with a well-characterized safety profile tailored to hormonal health needs.
Features
- Contains 60 mg raloxifene hydrochloride per tablet
- Selective estrogen receptor modulator (SERM) class
- Oral administration, once-daily dosing
- White, elliptical, film-coated tablets
- Available in 30- and 90-day supply blister packs
- Requires no routine bone turnover monitoring
- Stable at room temperature; no refrigeration needed
Benefits
- Significantly reduces the risk of vertebral fractures in postmenopausal women with osteoporosis
- Increases bone mineral density in the spine and hip, enhancing structural integrity
- Provides estrogen-like bone protection without proliferative effects on endometrium
- Lowers invasive breast cancer risk in eligible postmenopausal populations
- Supports long-term skeletal health with convenient once-daily oral regimen
- Avoids progestin co-therapy and associated side effects
Common use
Evista is primarily prescribed for the prevention and treatment of osteoporosis in postmenopausal women. It is also indicated for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis or those at high risk for invasive breast cancer. Healthcare providers may consider it for women who cannot or prefer not to take bisphosphonates or hormone replacement therapy.
Dosage and direction
The recommended dosage is one 60 mg tablet taken orally once daily, with or without food. Patients should swallow the tablet whole with plain water; it should not be crushed, chewed, or split. Consistency in daily timing is advised to maintain steady blood levels. Calcium and vitamin D supplementation is recommended unless dietary intake is sufficient. Treatment duration should be reassessed periodically based on bone density scans and clinical response.
Precautions
- Not recommended for premenopausal women or men
- Increased risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism); discontinue at least 72 hours before prolonged immobilization
- May cause hot flashes or leg cramps; usually diminish over time
- Use caution in patients with hepatic impairment
- Not intended for concurrent use with systemic estrogen therapy
- Monitor for signs of stroke or cardiovascular events in at-risk patients
- Regular breast and gynecologic exams recommended during treatment
Contraindications
- Active or past history of venous thromboembolic events
- Hypersensitivity to raloxifene or any component of the formulation
- Pregnancy, breastfeeding, or women who may become pregnant
- Significant hepatic impairment or cholestasis
- Concurrent use of cholestyramine or other anion exchange resins
Possible side effect
Common side effects include hot flashes, leg cramps, peripheral edema, flu-like symptoms, arthralgia, and sweating. Serious but less frequent adverse reactions may involve venous thromboembolism, fatal stroke, superficial thrombophlebitis, and retinal vein thrombosis. Rare cases of triglyceride elevation in patients with pre-existing hypertriglyceridemia have been reported.
Drug interaction
- Cholestyramine and other anion exchange resins reduce absorption; administer at least 2 hours apart
- Warfarin: monitor prothrombin time closely; may potentiate anticoagulant effect
- Highly protein-bound drugs (e.g., diazepam, diazoxide) may compete for binding sites
- Use caution with systemic estrogens or other hormone therapies
- No clinically significant interactions with corticosteroids, digoxin, or ampicillin
Missed dose
If a dose is missed, take it as soon as remembered on the same day. If missed entirely, resume the usual schedule the next day; do not double the dose. Consistent daily use is important for optimal effect, but occasional missed doses are not associated with significant loss of efficacy.
Overdose
Limited clinical experience exists with raloxifene overdose. Highest reported single dose was 600 mg without severe adverse effects. In case of suspected overdose, provide supportive care, including monitoring for thrombotic events and leg cramps. Dialysis is not expected to enhance elimination due to high protein binding.
Storage
Store at 25°C (77°F); excursions permitted between 15–30°C (59–86°F). Keep in the original blister pack to protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient needs and risks must be evaluated by a licensed physician.
Reviews
Clinical trials and long-term observational studies consistently demonstrate Evista’s efficacy in reducing vertebral fracture risk by approximately 30–50% over three years, with significant bone mineral density improvements of 2–3% in the spine and hip. Patient-reported outcomes note improved confidence in fracture prevention, though some report transient vasomotor symptoms. Healthcare providers appreciate its targeted mechanism and dual benefit in osteoporosis and breast cancer risk reduction, particularly in women contraindicated for estrogen therapy.